This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/pubchem-substance/
n11http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01102/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01102
rdf:type
n3:Drug
n3:description
Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .
n3:group
approved
n3:halfLife
Elimination half-life is approximately 8 minutes.
n3:indication
Used to elicit acute cardiovascular responses (cardiac stumulant), similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease (CAD) in patients who cannot exercise adequately.
owl:sameAs
n11:DB01102 n12:DB01102
dcterms:title
Arbutamine
adms:identifier
n6:DB01102 n14:50580 n15:54785 n16:PA164747979 n17:60789 n18:46509010
n3:mechanismOfAction
Arbutamine is a synthetic catecholamine with positive chronotropic and inotropic properties. The chronotropic (increase in heart rate) and inotropic (increase in force of contraction) effects of arbutamine serve to mimic exercise by increasing cardiac work (producing stress) and provoke myocardial ischemia in patients with compromised coronary arteries. The increase in heart rate caused by arbutamine is thought to limit regional subendocardial perfusion, thereby limiting tissue oxygenation. In functional assays, arbutamine is more selective for beta-adrenergic receptors than for alpha-adrenergic receptors. The beta-agonist activity of arbutamine provides cardiac stress by increasing heart rate, cardiac contractility, and systolic blood pressure. The degree of hypotension that occurs for a given chronotropic activity is less with arbutamine than, for example, with isoproterenol because alpha receptor activity is retained.
n3:patent
n9:5395970 n9:5234404
n3:synonym
Arbutaminum Arbutamina
n3:proteinBinding
58%
n3:IUPAC-Name
n4:271B3F58-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F5E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F5D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F5A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F5B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F5C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F56-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F6E-363D-11E5-9242-09173F13E4C5 n4:271B3F54-363D-11E5-9242-09173F13E4C5 n4:271B3F57-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F55-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:C01CA22
n3:H-Bond-Acceptor-Count
n4:271B3F64-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F65-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F5F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F60-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F62-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F61-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F63-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
128470-16-6
n3:Bioavailability
n4:271B3F6A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F6C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F6D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F69-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F68-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F6B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F59-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F66-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F67-363D-11E5-9242-09173F13E4C5